Interaction of cyclooxygenase-2 inhibitors and salicylate in gastric mucosal damage

被引:15
作者
Peskar, BM
Ehrlich, K
Peskar, BA
机构
[1] Ruhr Univ Bochum, Fac Med, Dept Expt Clin Med, D-44780 Bochum, Germany
[2] Graz Univ, Dept Clin & Expt Pharmacol, A-8010 Graz, Austria
关键词
sodium salicylate; cyclooxygenase-2; gastric mucosal damage; ischaemia-reperfusion; adaptive gastroprotection; nitric oxide (NO);
D O I
10.1016/S0014-2999(01)01524-2
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The interactions of sodium salicylate and the selective cyclooxygenase-2 inhibitors N-{2-(cyclohexyloxy)-4-nitrophenyl}-methanesulfonamide (NS-398) and 5,5-dimethyl-3-(3-fluorophenyl)-4-(4-methylsulfonyl)phenyl-2(5II)-furanone (DFU), dexamethasone and the nitric oxide (NO) synthase inhibitor N-G-nitro-L-arginine methylester (L-NAME) were examined in ischaemia-reperfusion damage and adaptive protection in the rat stomach. Ischaemia-reperfusion damage was substantially aggravated by pretreatment with NS-398 (4 mg/kg), DFU (2 mg/kg), dexamethasone (1 mg/kg) or L-NAME (3 and 10 mg/kg). Salicylate (0.01-0.05 mg/kg) reversed the aggravating effect of NS-398, DFU and dexamethasone, while the effect of L-NAME was counteracted by L-arginine (twice 400 mg/kg) but not salicylate (0.05 or 10 mg/kg). Instillation of 20% ethanol prevented mucosal damage induced by 70% ethanol. This adaptive gastroprotection was abolished by pretreatment with NS-398 (1 mg/kg), DFU (0.2 mg/kg) or L-NAME (10 mg/kg). Salicylate (0.01-0.05 mg/kg) reversed the inhibition of protection by NS-398 and DFU, while the effect of L-NAME (10 mg/kg) was antagonized by L-arginine (100 mg/kg) but not salicylate (0.05 mg/kg). The precise mechanism of the functional antagonism between extremely low doses of salicylate and selective cyclooxygenase-2 inhibitors remains to be investigated. (C) 2002 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 27 条
[1]   Re-addressing relative selectivities [J].
Botting, R ;
Vane, J .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (09) :312-312
[2]  
BUCCHI F, 1986, LEUKOTRIENES MED, V21, P111
[3]  
CERLETTI C, 1981, BIOCHIM BIOPHYS ACTA, V714, P122
[4]   Prevention of reoxygenation injury by sodium salicylate in isolated-perfused rat liver [J].
Colantoni, A ;
de Maria, N ;
Caraceni, P ;
Bernardi, M ;
Floyd, RA ;
Van Thiel, DH .
FREE RADICAL BIOLOGY AND MEDICINE, 1998, 25 (01) :87-94
[5]   Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFκB [J].
Cronstein, BN ;
Montesinos, MC ;
Weissmann, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1999, 96 (11) :6377-6381
[6]  
DAHL ML, 1983, LEUKOTRIENES MED, V12, P21
[7]   ANTAGONISM OF GASTROINTESTINAL ULCEROGENIC EFFECT OF SOME NONSTEROIDAL ANTI-INFLAMMATORY AGENTS BY SODIUM SALICYLATE [J].
EZER, E ;
PALOSI, E ;
HAJOS, G ;
SZPORNY, L .
JOURNAL OF PHARMACY AND PHARMACOLOGY, 1976, 28 (08) :655-656
[8]  
EZER E, 1984, ACTA PHYSIOL HUNG, V64, P355
[9]   A classification of NSAIDs according to the relative inhibition of cyclooxygenase isoenzymes [J].
Frolich, JC .
TRENDS IN PHARMACOLOGICAL SCIENCES, 1997, 18 (01) :30-34
[10]   NS-398, A NEW ANTIINFLAMMATORY AGENT, SELECTIVELY INHIBITS PROSTAGLANDIN-G/H SYNTHASE CYCLOOXYGENASE (COX-2) ACTIVITY IN-VITRO [J].
FUTAKI, N ;
TAKAHASHI, S ;
YOKOYAMA, M ;
ARAI, I ;
HIGUCHI, S ;
OTOMO, S .
PROSTAGLANDINS, 1994, 47 (01) :55-59